Know Cancer

forgot password

A Phase I Study to Evaluate the Safety and Pharmacokinetics of R306465 in Subjects With Advanced Solid Malignancies

Phase 1
18 Years
Not Enrolling

Thank you

Trial Information

A Phase I Study to Evaluate the Safety and Pharmacokinetics of R306465 in Subjects With Advanced Solid Malignancies

R306465, a histone deacetylase (HDAC) inhibitor, is a new drug in development for cancer. In
this study, the safety (the effect on the body) of R306465 in patients with advanced cancer
will be studied and the maximum dose that can be tolerated by these patients will be
determined. The absorption, break down, and elimination of the drug will be studied.
Antitumor activity of R306465 will be evaluated.

R306465 will be administered in a continuous regimen for 21 days followed by a 1-week rest
period, which constitutes a 28-day treatment cycle. The dose of R306465 will start low and
will be increased during the study in groups of 3 to 6 patients. If a group of patients does
not have severe side effects, the next group of patients will get a higher dose. The dose
will increase until some patients have severe side effects. The dose will then be decreased
to a dose level where severe side effects are observed in less than 1/3 of patients. The
amount of R306465 in the blood will be measured and the effect on the disease will be
evaluated in all patients.

Patients will be screened for eligibility within 4 weeks before study treatment is given.
The duration of treatment will depend on adverse effects and whether there is benefit from
the treatment.

The design of a cycle may be adjusted during the course of the study as guided by clinical
observations. The dosing regimen may be adjusted as guided by information on how rapidly
your body breaks down and eliminates the study drug. Patients will be informed if there are
changes in the design of a cycle or the dosing regimen.

During the first treatment cycle, patients are required to stay in the hospital for at least
3 nights. In addition there are 6 daytime visits during Cycles 1 and 2 (combined) that may
take up to 4 hours after the morning dose. From Cycle 3 onwards, there are only 2 daytime
visits per treatment cycle, and these visits usually take up less time.

Throughout the study, especially during Cycles 1 and 2, patients will undergo frequent blood
and urine tests, procedures to assess safety including heart function, and tests to assess
the course of the patient's illness. Two weeks after the last dose of the study drug,
patients are required to return to the study site for follow-up assessments. R306465 will be
administered orally once daily for 21 consecutive days followed by a 1-week rest period.
These 4 weeks will constitute 1 treatment cycle. The starting dose level will be 100mg. The
dose for each patient will be assigned at enrollment. On the basis of assessment by the
investigator, the patient may continue to receive study drug as long as there is clinical
benefit and in absence of intolerable side effects.

Inclusion Criteria:

- Confirmed solid malignancy that is metastatic or unresectable, and for which standard
curative or palliative measures does not exist or are no longer effective

- Performance status (based on the Eastern Cooperative Oncology Group assessments) of
<= 2

- Life expectancy > 3 months

- Adequate gastrointestinal absorption status

- Must meet protocol-defined criteria for lab assessments and adequate bone marrow,
liver, and kidney function.

Exclusion Criteria:

- Known central nervous system metastases

- Chemotherapy, radiotherapy, immunotherapy within 4 weeks before study drug
administration or incomplete recovery from preceding surgery

- Previous participation in a clinical study with histone deacetylase (HDAC) inhibitor
or another investigational anticancer agent within 4 weeks of dosing with R306465

- Patient has signs and symptoms of acute infection requiring systemic therapy

- Patient is not recovered from reversible toxicity of prior anticancer therapy.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determine the safety and maximum tolerated dose of R306465 when given as a daily oral dose during 3 weeks followed by a 1 week recovery period. Study the absorption, break down and elimination of R306465 following oral administration.

Principal Investigator

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial

Investigator Role:

Study Director

Investigator Affiliation:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.


United States: Institutional Review Board

Study ID:




Start Date:

September 2005

Completion Date:

October 2006

Related Keywords:

  • Neoplasms
  • Solid tumors
  • solid malignancies
  • neoplasms
  • refractory solid tumors
  • advanced solid tumors
  • Neoplasms